| 中文名稱 | 轉(zhuǎn)移生長因子β受體2抗體 |
| 別 名 | TGF beta R2; TGFBR2; TGF beta Receptor II; AAT 3; AAT3; FAA 3; FAA3; HNPCC6; MFS 2; MFS2; RIIC; TAAD 2; TAAD2; TbetaR II; TGF beta receptor type 2; TGF beta receptor type II; TGF beta type II receptor; TGFB R2; TGFbeta RII; TGFBR 2; TGFBR2; TGFR 2; TGFR2; Transforming growth factor beta receptor II; Transforming growth factor beta receptor type II; |
| 研究領(lǐng)域 | 腫瘤 細胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 生長因子和激素 激酶和磷酸酶 細胞膜受體 細胞分化 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, Cow, (predicted: Chicken, Pig, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 62kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human TGF beta R2:241-330/567 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | This gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized. Function: Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. Subunit: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric ligands assemble a functional receptor composed of two TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate the kinetics of assembly of the receptor and may explain the different biological activities of TGFB1, TGFB2 and TGFB3. Interacts with DAXX. Interacts with TCTEX1D4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta receptor. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Post-translational modifications: Phosphorylated on a Ser/Thr residue in the cytoplasmic domain. DISEASE: Defects in TGFBR2 are the cause of hereditary non-polyposis colorectal cancer type 6 (HNPCC6) [MIM:614331]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases. Similarity: Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily. Contains 1 protein kinase domain. SWISS: P37173 Gene ID: 7048 Database links: Entrez Gene: 7048 Human Entrez Gene: 21813 Mouse Omim: 190182 Human SwissProt: P37173 Human SwissProt: Q62312 Mouse Unigene: 604277 Human Unigene: 82028 Human Unigene: 172346 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 細胞膜受體（Membrane Receptors) TGFβR2及家族在進化過程中結(jié)構(gòu)和功能高度保守。參與細胞因子信號傳導(dǎo)，調(diào)節(jié)多種細胞的生長、分化，在胚胎發(fā)育、組織器官形態(tài)發(fā)生、細胞的分化、增值及免疫調(diào)節(jié)等方面都起著重要作用。此抗體主要用于散發(fā)性胃癌、結(jié)腸癌及T細胞淋巴瘤和頭頸部腫瘤方面的研究。 |
| 產(chǎn)品圖片 |  Sample:Kidney (Mouse) Lysate at 40 ug Primary: Anti-TGF beta Receptor II (bs-0117R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 62 kD Observed band size: 62 kD  Sample: HepG2 Cell Lysate at 40 ugPrimary: Anti- TGF beta RECEPTOR Ⅱ(bs-0117R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 62 kD Observed band size: 62 kD  Sample:Brain(Mouse) Lysate at 30 ug Brain(Rat) Lysate at 30 ug Primary: Anti-TGF-beta-R2/TGFBR2 (bs-0117R) at 1/300 dilution Secondary:IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 62 kD Observed band size: 62 kD  Tissue/cell:rabbit carotid artery; 4% Paraformaldehyde-fixed and paraffin-embedded;Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-TGF-beta-R2/TGFBR2 Polyclonal Antibody, Unconjugated(bs-0117R) 1:600, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining |
我要詢價
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯(lián)系方式不會被公開)
*內(nèi)容：
